Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: CLARITIN-D 24 HOUR

« Back to Dashboard
Claritin-d 24 Hour is a drug marketed by Bayer Healthcare Llc and is included in one NDA. It is available from one supplier.

The generic ingredient in CLARITIN-D 24 HOUR is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

Summary for Tradename: CLARITIN-D 24 HOUR

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list6

Clinical Trials for: CLARITIN-D 24 HOUR

Bioequivalnce Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fasting Conditions
Status: Completed Condition: Healthy

Comparative Effectiveness of Two Associations of Loratadine + Pseudoephedrine, Cloratadd-d ® (Coated Pill) Produced by the Laboratory Ems and Claritin-d ® (dräger), Produced by Schering-plough in Patients With Perennial Allergic Rhinitis
Status: Completed Condition: Perennial Allergic Rhinitis

Clinical Trial Of The Effectiveness Of The Product Cloratadd D (Loratadine + Pseudoephedrine Sulfate) Produced By The Laboratory EMS S/A, Compared To The Drug Claritin D Produced By Schering-Plough S/A, In Patients With Allergic Rhinitis
Status: Withdrawn Condition: Allergic Rhinitis

Bioequivalence Study of Loratadine / Pseudoephedrine Sulfate 10/ 240 mg Extended-Release Tablets Under Fed Conditions
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc
CLARITIN-D 24 HOUR
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL020470-002Nov 27, 2002OTCYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CLARITIN-D 24 HOUR

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Healthcare Llc
CLARITIN-D 24 HOUR
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL020470-002Nov 27, 20024,659,716*PED<disabled>
Bayer Healthcare Llc
CLARITIN-D 24 HOUR
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL020470-002Nov 27, 20024,863,931*PED<disabled>
Bayer Healthcare Llc
CLARITIN-D 24 HOUR
loratadine; pseudoephedrine sulfate
TABLET, EXTENDED RELEASE;ORAL020470-002Nov 27, 20025,314,697*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc